消息人士透露，大约两个月前，在诺和诺德丹麦总部举行的一次闭门会议上，印度团队表达了担忧，称如果Wegovy不能尽早在印度推出，公司可能会在这一市场落后于礼来。① It is reported that the novo-nordisk a/s india team recently proposed to advance the launch time to 2025, which is roughly the same as the expected time for eli lilly and co to launch its weight loss drug Mounjaro; ② The novo-nordisk a/s india team stated that if Wegovy cannot be launched in india soon, the company may fall behind eli lilly and co in this market.
On December 3, a report from Caixin News (editor: Xia Junxiong) cited sources stating that the Danish pharmaceutical giant $Novo-Nordisk A/S (NVO.US)$ has been urging the company's senior management to launch its star weight loss drug Wegovy locally as soon as possible to avoid lagging behind competitors in india, a potentially huge market. $Eli Lilly and Co (LLY.US)$ The company.
Senior management at novo-nordisk a/s previously stated that once regulatory approval is obtained and supply is sufficient, Wegovy could enter india in 2026. However, the novo-nordisk a/s india team recently proposed to advance the launch time to 2025, which is roughly the same as the expected time for eli lilly and co to launch its weight loss drug Mounjaro.
Sources revealed that about two months ago, during a closed-door meeting held at the novo-nordisk a/s headquarters in Denmark, the india team expressed concerns, stating that if Wegovy cannot be launched in india soon, the company may fall behind eli lilly and co in this market.
The active ingredient of Wegovy is the same as Novo-Nordisk's diabetes drug Ozempic, which is Semaglutide. Eli Lilly and Co's weight loss drug Zepbound and diabetes drug Mounjaro also share the same ingredient, which is Tirzepatide.
All four drugs belong to GLP-1 (glucagon-like peptide-1) receptor agonists, which work by suppressing the patient's appetite and slowing gastric emptying to achieve weight loss.
It is reported that Novo-Nordisk received approval from india's regulatory institutions for its injectable Semaglutide at the end of 2022.
Novo-Nordisk and Eli Lilly and Co are both expanding production capacity to compete for market dominance in weight loss drugs, with some analysts expecting the annual sales of this market to reach 150 billion dollars in the next decade.
India has a population of over 1.4 billion, and its obesity rate has been rising in recent years. According to a survey conducted by the Indian government from 2019 to 2021, 24% of women and nearly 23% of men aged 15 to 49 were overweight or obese, up from 20.6% and 19% in 2015-2016.
However, Novo-Nordisk and Eli Lilly and Co face challenges from generic drugs in the indian market. Indian generic manufacturers like Cipla and Dr. Reddy's are developing generics of Wegovy, with the specific launch date depending on patent expiration. Meanwhile, India's largest pharmaceutical company, Sun Pharmaceutical, is developing an independently researched experimental GLP weight loss drug.
Editor / jayden
